250 related articles for article (PubMed ID: 32623905)
1. Intronic CRISPR Repair in a Preclinical Model of Noonan Syndrome-Associated Cardiomyopathy.
Hanses U; Kleinsorge M; Roos L; Yigit G; Li Y; Barbarics B; El-Battrawy I; Lan H; Tiburcy M; Hindmarsh R; Lenz C; Salinas G; Diecke S; Müller C; Adham I; Altmüller J; Nürnberg P; Paul T; Zimmermann WH; Hasenfuss G; Wollnik B; Cyganek L
Circulation; 2020 Sep; 142(11):1059-1076. PubMed ID: 32623905
[TBL] [Abstract][Full Text] [Related]
2. Inducible Pluripotent Stem Cell-Derived Cardiomyocytes Reveal Aberrant Extracellular Regulated Kinase 5 and Mitogen-Activated Protein Kinase Kinase 1/2 Signaling Concomitantly Promote Hypertrophic Cardiomyopathy in RAF1-Associated Noonan Syndrome.
Jaffré F; Miller CL; Schänzer A; Evans T; Roberts AE; Hahn A; Kontaridis MI
Circulation; 2019 Jul; 140(3):207-224. PubMed ID: 31163979
[TBL] [Abstract][Full Text] [Related]
3.
Higgins EM; Bos JM; Dotzler SM; John Kim CS; Ackerman MJ
Circ Genom Precis Med; 2019 Nov; 12(11):e002648. PubMed ID: 31638832
[TBL] [Abstract][Full Text] [Related]
4. Determining the Pathogenicity of a Genomic Variant of Uncertain Significance Using CRISPR/Cas9 and Human-Induced Pluripotent Stem Cells.
Ma N; Zhang JZ; Itzhaki I; Zhang SL; Chen H; Haddad F; Kitani T; Wilson KD; Tian L; Shrestha R; Wu H; Lam CK; Sayed N; Wu JC
Circulation; 2018 Dec; 138(23):2666-2681. PubMed ID: 29914921
[TBL] [Abstract][Full Text] [Related]
5. Noonan syndrome-associated biallelic LZTR1 mutations cause cardiac hypertrophy and vascular malformations in zebrafish.
Nakagama Y; Takeda N; Ogawa S; Takeda H; Furutani Y; Nakanishi T; Sato T; Hirata Y; Oka A; Inuzuka R
Mol Genet Genomic Med; 2020 Mar; 8(3):e1107. PubMed ID: 31883238
[TBL] [Abstract][Full Text] [Related]
6. Preclinical evaluation of CRISPR-based therapies for Noonan syndrome caused by deep-intronic
Knauer C; Haltern H; Schoger E; Kügler S; Roos L; Zelarayán LC; Hasenfuss G; Zimmermann WH; Wollnik B; Cyganek L
Mol Ther Nucleic Acids; 2024 Mar; 35(1):102123. PubMed ID: 38333672
[TBL] [Abstract][Full Text] [Related]
7. Dominant Noonan syndrome-causing LZTR1 mutations specifically affect the Kelch domain substrate-recognition surface and enhance RAS-MAPK signaling.
Motta M; Fidan M; Bellacchio E; Pantaleoni F; Schneider-Heieck K; Coppola S; Borck G; Salviati L; Zenker M; Cirstea IC; Tartaglia M
Hum Mol Genet; 2019 Mar; 28(6):1007-1022. PubMed ID: 30481304
[TBL] [Abstract][Full Text] [Related]
8. Isogenic models of hypertrophic cardiomyopathy unveil differential phenotypes and mechanism-driven therapeutics.
Bhagwan JR; Mosqueira D; Chairez-Cantu K; Mannhardt I; Bodbin SE; Bakar M; Smith JGW; Denning C
J Mol Cell Cardiol; 2020 Aug; 145():43-53. PubMed ID: 32531470
[TBL] [Abstract][Full Text] [Related]
9. CRISPR correction of the PRKAG2 gene mutation in the patient's induced pluripotent stem cell-derived cardiomyocytes eliminates electrophysiological and structural abnormalities.
Ben Jehuda R; Eisen B; Shemer Y; Mekies LN; Szantai A; Reiter I; Cui H; Guan K; Haron-Khun S; Freimark D; Sperling SR; Gherghiceanu M; Arad M; Binah O
Heart Rhythm; 2018 Feb; 15(2):267-276. PubMed ID: 28917552
[TBL] [Abstract][Full Text] [Related]
10. Delineation of LZTR1 mutation-positive patients with Noonan syndrome and identification of LZTR1 binding to RAF1-PPP1CB complexes.
Umeki I; Niihori T; Abe T; Kanno SI; Okamoto N; Mizuno S; Kurosawa K; Nagasaki K; Yoshida M; Ohashi H; Inoue SI; Matsubara Y; Fujiwara I; Kure S; Aoki Y
Hum Genet; 2019 Jan; 138(1):21-35. PubMed ID: 30368668
[TBL] [Abstract][Full Text] [Related]
11. Noonan syndrome patient-specific induced cardiomyocyte model carrying SOS1 gene variant c.1654A>G.
Gurusamy N; Rajasingh S; Sigamani V; Rajasingh R; Isai DG; Czirok A; Bittel D; Rajasingh J
Exp Cell Res; 2021 Mar; 400(1):112508. PubMed ID: 33549576
[TBL] [Abstract][Full Text] [Related]
12. Delineation of dominant and recessive forms of LZTR1-associated Noonan syndrome.
Pagnamenta AT; Kaisaki PJ; Bennett F; Burkitt-Wright E; Martin HC; Ferla MP; Taylor JM; Gompertz L; Lahiri N; Tatton-Brown K; Newbury-Ecob R; Henderson A; Joss S; Weber A; Carmichael J; Turnpenny PD; McKee S; Forzano F; Ashraf T; Bradbury K; Shears D; Kini U; de Burca A; ; Blair E; Taylor JC; Stewart H
Clin Genet; 2019 Jun; 95(6):693-703. PubMed ID: 30859559
[TBL] [Abstract][Full Text] [Related]
13. Phenotypic Screening Using Patient-Derived Induced Pluripotent Stem Cells Identified Pyr3 as a Candidate Compound for the Treatment of Infantile Hypertrophic Cardiomyopathy.
Sakai T; Naito AT; Kuramoto Y; Ito M; Okada K; Higo T; Nakagawa A; Shibamoto M; Yamaguchi T; Sumida T; Nomura S; Umezawa A; Miyagawa S; Sawa Y; Morita H; Lee JK; Shiojima I; Sakata Y; Komuro I
Int Heart J; 2018 Sep; 59(5):1096-1105. PubMed ID: 30101858
[TBL] [Abstract][Full Text] [Related]
14. Pathogenic mechanism and gene correction for LQTS-causing double mutations in KCNQ1 using a pluripotent stem cell model.
Wang Z; Wang L; Liu W; Hu D; Gao Y; Ge Q; Liu X; Li L; Wang Y; Wang S; Li C
Stem Cell Res; 2019 Jul; 38():101483. PubMed ID: 31226583
[TBL] [Abstract][Full Text] [Related]
15. Functional and transcriptomic insights into pathogenesis of R9C phospholamban mutation using human induced pluripotent stem cell-derived cardiomyocytes.
Ceholski DK; Turnbull IC; Kong CW; Koplev S; Mayourian J; Gorski PA; Stillitano F; Skodras AA; Nonnenmacher M; Cohen N; Björkegren JLM; Stroik DR; Cornea RL; Thomas DD; Li RA; Costa KD; Hajjar RJ
J Mol Cell Cardiol; 2018 Jun; 119():147-154. PubMed ID: 29752948
[TBL] [Abstract][Full Text] [Related]
16. Generation of a genetically-modified induced pluripotent stem cell line harboring a Noonan syndrome-associated gene variant MRAS p.G23V.
Busley AV; Cyganek L
Stem Cell Res; 2023 Jun; 69():103108. PubMed ID: 37141804
[TBL] [Abstract][Full Text] [Related]
17. The Noonan Syndrome Gene
Sewduth RN; Pandolfi S; Steklov M; Sheryazdanova A; Zhao P; Criem N; Baietti MF; Lechat B; Quarck R; Impens F; Sablina AA
Circ Res; 2020 May; 126(10):1379-1393. PubMed ID: 32175818
[TBL] [Abstract][Full Text] [Related]
18. Molecular and cellular evidence for the impact of a hypertrophic cardiomyopathy-associated RAF1 variant on the structure and function of contractile machinery in bioartificial cardiac tissues.
Nakhaei-Rad S; Haghighi F; Bazgir F; Dahlmann J; Busley AV; Buchholzer M; Kleemann K; Schänzer A; Borchardt A; Hahn A; Kötter S; Schanze D; Anand R; Funk F; Kronenbitter AV; Scheller J; Piekorz RP; Reichert AS; Volleth M; Wolf MJ; Cirstea IC; Gelb BD; Tartaglia M; Schmitt JP; Krüger M; Kutschka I; Cyganek L; Zenker M; Kensah G; Ahmadian MR
Commun Biol; 2023 Jun; 6(1):657. PubMed ID: 37344639
[TBL] [Abstract][Full Text] [Related]
19. Autosomal recessive Noonan syndrome associated with biallelic LZTR1 variants.
Johnston JJ; van der Smagt JJ; Rosenfeld JA; Pagnamenta AT; Alswaid A; Baker EH; Blair E; Borck G; Brinkmann J; Craigen W; Dung VC; Emrick L; Everman DB; van Gassen KL; Gulsuner S; Harr MH; Jain M; Kuechler A; Leppig KA; McDonald-McGinn DM; Can NTB; Peleg A; Roeder ER; Rogers RC; Sagi-Dain L; Sapp JC; Schäffer AA; Schanze D; Stewart H; Taylor JC; Verbeek NE; Walkiewicz MA; Zackai EH; Zweier C; ; Zenker M; Lee B; Biesecker LG
Genet Med; 2018 Oct; 20(10):1175-1185. PubMed ID: 29469822
[TBL] [Abstract][Full Text] [Related]
20. iPSC-Based Modeling of Variable Clinical Presentation in Hypertrophic Cardiomyopathy.
Escribá R; Larrañaga-Moreira JM; Richaud-Patin Y; Pourchet L; Lazis I; Jiménez-Delgado S; Morillas-García A; Ortiz-Genga M; Ochoa JP; Carreras D; Pérez GJ; de la Pompa JL; Brugada R; Monserrat L; Barriales-Villa R; Raya A
Circ Res; 2023 Jul; 133(2):108-119. PubMed ID: 37317833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
